Loading…
NovoCure Limited is projected to rise to $18.59 by 2027, a +14% move from its current price of $16.30. NVCR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $15.70 | $16.30 | $16.91 | -0.03% |
| Jul 15 | $15.46 | $16.29 | $17.17 | -0.05% |
| Jul 16 | $15.27 | $16.29 | $17.37 | -0.08% |
| Jul 17 | $15.11 | $16.28 | $17.54 | -0.11% |
| Jul 18 | $14.98 | $16.28 | $17.69 | -0.13% |
| Jul 19 | $14.86 | $16.27 | $17.83 | -0.16% |
| Jul 20 | $14.74 | $16.27 | $17.95 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.74 | $16.27 | $17.95 | -0.19% |
| Week 2 | $14.13 | $16.24 | $18.66 | -0.38% |
| Week 3 | $13.67 | $16.21 | $19.22 | -0.56% |
| Week 4 | $13.29 | $16.18 | $19.70 | -0.75% |
| Week 5 | $12.96 | $16.15 | $20.12 | -0.94% |
| Week 6 | $12.66 | $16.12 | $20.51 | -1.12% |
| Week 7 | $12.40 | $16.09 | $20.87 | -1.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NovoCure Limited is an oncology company that develops, manufactures, and commercializes tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure is currently trading at $17.20 with a market capitalization of $1.83B and a market rank of 5459.
The near-term forecast for 2026 shows an average price of $17.20, with a low of $10.03, a high of $23.45, and a neutral sentiment; the ROI is 0%. This establishes a flatish starting point before longer-term movement.
Looking further out, the forecast outlines a bullish path with rising averages and sizable upside. The 2027–2050 forecasts show progressively higher average prices, with 2030 at $39.03 and 2050 at $224.23, and maximums up to $62.39 in 2030 and $489.56 in 2050.
A major floor 36.5% below — a decisive break under it would weaken the trend.
The nearest floor, 16.5% below — buyers have tended to step in here.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 24.8% above — clearing it would confirm fresh momentum.
Key NVCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.20 | Sell | $16.85 | Sell |
| MA 10 | $16.50 | Sell | $16.63 | Sell |
| MA 20 | $16.26 | Buy | $16.46 | Sell |
| MA 50 | $16.70 | Sell | $15.96 | Buy |
| MA 100 | $14.37 | Buy | $15.05 | Buy |
| MA 200 | $13.59 | Buy | $14.66 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.41 | Neutral |
| Stoch RSI (14) | 59.62 | Neutral |
| CCI (20) | 1.94 | Neutral |
| Williams %R (14) | -34.55 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 15.36 | Buy |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 65.45 | Neutral |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | 0.58 | Buy |
| Ultimate (7,14,28) | 62.14 | Neutral |
| Momentum (10) | 1.25 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 17.46 | Sell |
| ADX (14) | 14.48 | Neutral |
| ATR (14) | 0.57 | Info |
The 30-day technical picture remains bullish overall, with RSI14 at 60 and a sentiment label of BULLISH.
Key moving averages are SMA50 at $16.24 and SMA200 at $13.48, providing near-term support and trend context. Support is listed at $13.61 and resistance at $18.26, framing a defined range.
The 30-day price range is $13.16 to $22.47, indicating potential upside beyond the current $17.20 level while keeping downside risk in a clearly bounded area.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.03 | $16.30 | $21.26 | 0% | Neutral | |
| $14.30 | $18.59 | $25.84 | +14% | Neutral | |
| $17.52 | $23.69 | $34.55 | +45% | Bullish | |
| $20.04 | $28.02 | $42.40 | +72% | Bullish | |
| $22.59 | $32.52 | $50.77 | +100% | Bullish | |
| $24.39 | $36.08 | $57.86 | +121% | Bullish | |
| $22.51 | $34.16 | $56.10 | +110% | Bullish | |
| $23.92 | $37.19 | $62.41 | +128% | Bullish | |
| $26.35 | $41.92 | $71.76 | +157% | Bullish | |
| $31.24 | $50.82 | $88.61 | +212% | Bullish | |
| $36.23 | $65.34 | $122.94 | +301% | Bullish | |
| $72.49 | $157.72 | $330.90 | +868% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $10.03 | $16.30 | $19.31 | +0.00% |
| August 2026 | $12.99 | $15.48 | $19.04 | -5.02% |
| September 2026 | $13.22 | $15.90 | $19.86 | +2.73% |
| October 2026 | $13.59 | $16.48 | $20.84 | +3.65% |
| November 2026 | $13.30 | $16.24 | $20.76 | -1.46% |
| December 2026 | $13.40 | $16.48 | $21.26 | +1.44% |
Click any year to see its month-by-month NVCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NVCR is projected to trade between $10.03 and $21.26, averaging $16.30 — a potential gain of 0% from today's $16.30. Price action looks broadly range-bound.
NovoCure Limited's 2027 outlook centres on $18.59, within a $14.30 to $25.84 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, NVCR could reach as high as $34.55, with a base case around $23.69 and support toward $17.52 — roughly +45% from $16.30. Momentum favours further upside here.
Expect NVCR to range from $20.04 to $42.40 through 2029. The $28.02 average target implies a +72% move from current prices. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NVCR price prediction for 2030 points to an average of $32.52 (low $22.59, high $50.77) — a potential gain of +100% on today's $16.30. Momentum favours further upside here.
In 2031, NVCR is projected to trade between $24.39 and $57.86, averaging $36.08 — a potential gain of +121% from today's $16.30. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
NovoCure Limited's 2032 outlook centres on $34.16, within a $22.51 to $56.10 range. That is -5% versus the projected 2031 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2033, NVCR could reach as high as $62.41, with a base case around $37.19 and support toward $23.92 — roughly +128% from $16.30. Buyers look set to stay in control over this stretch.
Expect NVCR to range from $26.35 to $71.76 through 2034. The $41.92 average target implies a +157% move from current prices. That is up +13% on the projected 2033 average. Momentum favours further upside here.
The NVCR price prediction for 2035 points to an average of $50.82 (low $31.24, high $88.61) — a potential gain of +212% on today's $16.30. Buyers look set to stay in control over this stretch.
In 2040, NVCR is projected to trade between $36.23 and $122.94, averaging $65.34 — a potential gain of +301% from today's $16.30. That is up +29% on the projected 2035 average. Momentum favours further upside here.
NovoCure Limited's 2050 outlook centres on $157.72, within a $72.49 to $330.90 range. That is up +141% on the projected 2040 average. That marks a +868% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVCR today (≈ 61.349693 NVCR) could be worth
$9,676.09
+$8,676.09 (+868%) by 2050 · US Dollar
Based on the average projected NVCR price of $157.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVCRwould be worth at today's price.
$1,000 invested in NVCR on Jul 10, 2025 (≈ 54.171184 NVCR) would be worth
$882.99
-$117.01 (-11.7%) today · 0.88× · US Dollar
Based on a NVCR entry price of $18.46 vs. today's $16.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.2 | $947.67 | -5.2% |
| 1 month ago | $16.65 | $978.98 | -2.1% |
| 3 months ago | $10.58 | $1,540.64 | +54.1% |
| 6 months ago | $14.18 | $1,149.51 | +15.0% |
| 1 year ago | $18.46 | $882.99 | -11.7% |
| All time (5.0y) ago | $184.68 | $88.26 | -91.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVCR forecast.
Our base-case forecast reaches $33.00 around 2031.
Implied market cap at $33.00: $3.82B
The multi-year forecast shows a bullish trajectory with notable growth in average prices and substantial ROIs.
For 2027 the average is $20.72 with ROI 20.4% and bullish sentiment, rising to an average of $27.18 in 2028 (ROI 58%) and $33.62 in 2029 (ROI 95.4%). By 2030 the average is $39.03 (ROI 126.9%) and sentiment remains BULLISH, with further gains expected through 2031–2035 (2031 avg $43.29, ROI 151.7%; 2032 avg $41.88, ROI 143.5%; 2033 avg $45.82, ROI 166.4%; 2034 avg $53.50, ROI 211.1%; 2035 avg $67.51, ROI 292.5%).
The forecast extends to 2040 with an average of $85.73 (ROI 398.4%) and to 2050 with an average of $224.23 (ROI 1203.7%), both labeled BULLISH. The path implies substantial upside relative to the current level but remains subject to the risks inherent in any forecast.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $39.03 with a min of $26.47 and a max of $62.39, and a forecast ROI of 126.9% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with rising averages and increasing ROIs (e.g., 2027 ROI 20.4%, 2028 ROI 58%, 2029 ROI 95.4%, and higher through 2050), though the 2026 start is neutral. These are estimates, not guarantees.
Yes. By 2050, the min is $100.90 and the max is $489.56 with an average of $224.23 and a ROI of 1203.7%, indicating the possibility of exceeding $100 in that horizon.
Current price is $17.20 and market cap is $1.83B.
RSI14 is 60 with a BULLISH sentiment. SMA50 is $16.24 and SMA200 is $13.48. Support is $13.61 and resistance is $18.26. The 30-day range is $13.16 to $22.47.
NovoCure Limited Community Discussion
0Share your NovoCure Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.